A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with MDS, CMML, and AML

Low-dose oral DEC-C among patients with low-risk MDS

Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Phase I/II study of decitabine/cedazuridine (ASTX727), venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndromes

A randomized phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant acute myeloid leukemia: a MyeloMATCH substudy (MM10A-S03)

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician’s choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in acute myeloid leukemia

Trial in progress: a phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes and acute myeloid leukemia

Trial in progress: a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Time burden of treatment with parenteral hypomethylating agents in combination with venetoclax among patients with newly diagnosed acute myeloid leukemia

Real-world characteristics, treatment modifications, and outcomes for patients with acute myeloid leukemia receiving hypomethylating agents plus venetoclax as first-line therapy

Trial-level meta-analysis of minimal residual disease and progression-free survival in follicular lymphoma